223 related articles for article (PubMed ID: 25072631)
1. Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model.
Lin J; Shigdar S; Fang DZ; Xiang D; Wei MQ; Danks A; Kong L; Li L; Qiao L; Duan W
PLoS One; 2014; 9(7):e103736. PubMed ID: 25072631
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer.
Lin J; Yu Y; Shigdar S; Fang DZ; Du JR; Wei MQ; Danks A; Liu K; Duan W
PLoS One; 2012; 7(11):e49277. PubMed ID: 23145140
[TBL] [Abstract][Full Text] [Related]
3. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
[TBL] [Abstract][Full Text] [Related]
4. Preparation of Liposome Gel by Calcium Cross-Linking Induces the Long-Term Release of DOX to Improve the Antitumor Effect.
Wang L; Wang Y; Ye Z; Yu Y; Wang C; Qiu L; Du X; Zhou S; Wang J; Jiang P
Mol Pharm; 2024 May; 21(5):2394-2405. PubMed ID: 38647653
[TBL] [Abstract][Full Text] [Related]
5. Environmentally Self-Adaptative Nanocarriers Suppress Glioma Proliferation and Stemness via Codelivery of shCD163 and Doxorubicin.
Liu J; Zhang Y; Chen T; Chen H; He H; Jin T; Wang J; Ke Y
ACS Appl Mater Interfaces; 2020 Nov; 12(47):52354-52369. PubMed ID: 33196179
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
7. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
9. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo.
Zhu Y; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z
J Control Release; 2016 Jul; 233():29-38. PubMed ID: 27178807
[TBL] [Abstract][Full Text] [Related]
10. Surface-Modified Nanoerythrocyte Loading DOX for Targeted Liver Cancer Chemotherapy.
Wang Y; Chen X; He D; Zhou Y; Qin L
Mol Pharm; 2018 Dec; 15(12):5728-5740. PubMed ID: 30359027
[TBL] [Abstract][Full Text] [Related]
11. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
Siegal T; Horowitz A; Gabizon A
J Neurosurg; 1995 Dec; 83(6):1029-37. PubMed ID: 7490617
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
[TBL] [Abstract][Full Text] [Related]
14. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.
Xiao K; Luo J; Li Y; Lee JS; Fung G; Lam KS
J Control Release; 2011 Oct; 155(2):272-81. PubMed ID: 21787818
[TBL] [Abstract][Full Text] [Related]
15. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
16. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
17. Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors.
Kuo PH; Teng YH; Cin AL; Han W; Huang PW; Wang LH; Chou YT; Yang JL; Tseng YL; Kao M; Chang MD
Drug Deliv; 2020 Dec; 27(1):542-555. PubMed ID: 32241176
[TBL] [Abstract][Full Text] [Related]
18. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
19. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies.
Zhang X; Sun X; Li J; Zhang X; Gong T; Zhang Z
Pharmazie; 2011 Jul; 66(7):496-505. PubMed ID: 21812324
[TBL] [Abstract][Full Text] [Related]
20. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
